CagriSema is a fixed-combination research peptide formulation containing Cagrilintide (2.5mg), a long-acting amylin analogue, and Semaglutide (5mg), a glucagon-like peptide-1 (GLP-1) receptor agonist. Together, these two compounds engage complementary hormonal pathways involved in energy homeostasis, glycaemic control, and satiety signalling.
Cagrilintide acts on amylin receptors in the central nervous system — particularly in the area postrema and nucleus tractus solitarius — to reduce gastric emptying, suppress glucagon secretion, and promote post-prandial satiety. Semaglutide simultaneously activates GLP-1 receptors in the pancreas and brain, enhancing insulin secretion, reducing appetite signalling, and modulating reward pathways associated with food intake.
The combination has attracted significant interest in metabolic research, with studies investigating its synergistic potential for greater weight reduction and glycaemic improvement compared to either agent alone. This dual-mechanism approach mirrors the investigational profile of combination cardiometabolic therapies currently being evaluated in clinical research settings.
Molecular Formula (Cagrilintide): C₁₆₇H₂₆₃N₄₃O₄₉; Molecular Formula (Semaglutide): C₁₈₇H₂₉₁N₄₅O₅₉. Combined molecular weight: approximately 10,100 g/mol. Purity: >98% by HPLC. Store lyophilised product at -20°C; once reconstituted, store at 4°C and use within 28 days.
Molecular Formula
Cagrilintide: C₁₆₇H₂₆₃N₄₃O₄₉ / Semaglutide: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight
Cagrilintide: ~3,895 g/mol / Semaglutide: ~4,113.6 g/mol / Combined: ~8,008.6 g/mol
Purity
>98% (HPLC)
CAS Number
Cagrilintide: 2092949-45-2 / Semaglutide: 910463-68-2
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity and body weight regulation, Type 2 diabetes and glycaemic control, Appetite and satiety signalling, Cardiometabolic syndrome studies, GLP-1 and amylin receptor pharmacology
For research purposes only. Not for human use.
Reviews
There are no reviews yet.